Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 16Terminated 12Recruiting 7Unknown 4Withdrawn 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 132Lymphoid 35Other hematologic neoplasm 24Gastrointestinal 4Thoracic 3Genitourinary 2CNS 2Tumor-Agnostic 1Other 1Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1

Interventions

Carboplatin 131pembrolizumab 112Pemetrexed 91Cisplatin 86durvalumab 64Paclitaxel 58osimertinib 55Nivolumab 55Docetaxel 44atezolizumab 41Etoposide 30Radiotherapy 28Radiosurgery 26Gemcitabine 26Specimen Handling 24Ipilimumab 23Taxes 19Magnetic Resonance Spectroscopy 19amivantamab 16Drug Therapy 15Bevacizumab 15130-nm albumin-bound paclitaxel 15Radiation 14Platinum 14Immunoglobulin G 14Disulfides 14cemiplimab 13Crizotinib 13lazertinib 11Cyclophosphamide 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Dexamethasone × Thoracic × Clear all
NCT06305754 2026-05-22

MK-2870-009

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
520 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Janssen Research & Development, LLC

Phase 2 Active not recruiting
68 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡